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Cancers of the appendix are rare. Most of them are found accidentally on appendectomies performed for appendicitis. When
reviewed, majority of the tumors were carcinoid, adenoma, and lymphoma. Adenocarcinomas of appendix are only 0.08%
of all cancers and the treatment remains controversial. Here we are reporting a 46-year-old male presented with symptoms
of appendicitis, diagnosed with adenocarcinoma of the appendix. The patient was treated with appendectomy and refused
further surgical intervention to complete hemicolectomy. Up to date, he remains asymptomatic. We performed literature review
of the tumors of the appendix. Most of the benign conditions are treated with surgery alone. Lymphomas require CHOP-
like chemotherapy and carcinoid syndrome treatment with somatostatin analogues. It is generally recommended that right
hemicolectomy is the preferred treatment for adenocarcinoma of appendix. The role of chemotherapy is unclear due to lacking
randomized trials but seems to be accepted if there is lymph node involvement or peritoneal seeding.
1.Introduction
The function of appendix in humans is unclear, although it
is thought to possibly play a role in the immune system. Very
rarely, the appendix may become cancerous. Cancer of the
appendix may cause appendicitis or rupture of appendicitis.
Mostly this is the ﬁrst symptom of appendix cancer.
The majority of appendiceal tumors are carcinoids, while
the remaining 10% to 20% are mucinous cystadenocar-
cinoma, adenocarcinoma, lymphosarcoma, paraganglioma,
and granular-cell tumors. Most common symptoms include
acute pain in right lower quadrant and other symptoms of
inﬂammation like fever, leukocytosis, and so forth. Appen-
dectomy is performed as clinically indicated. If a mass in
the appendix is encountered incidentally during the course
of abdominal surgery, an appendectomy is performed with
frozen-section analysis of the mass. Most masses are benign
mucoceles or very small carcinoids. They do not require
any further management. However, if lymphoma or larger
carcinoid was identiﬁed, chemotherapy or more extensive
surgery will be required. When the mass is adenocarcinoma,
the treatment algorithm is less deﬁned as the data remain
controversial.
2.CaseReport
We are reporting a 46-year-old African-American male pre-
sented to the emergency room with lower back pain sec-
ondary to a motor vehicle accident in 2009. After admission,
patient complained of right lower quadrant pain, low-grade
fever, and nausea. Laboratory showed leukocytosis. Patient
was taken to the operating room and underwent appendec-
tomy. During the surgery, the appendix was found to be
gangrenous and perforated with an associated abscess. The
surgical pathology showed adenocarcinoma of appendix,
moderately diﬀerentiated with no lymphovascular invasion,
and acute appendicitis. The tumor was found to be 2.3cm,
grade 2, mucin-producing adenocarcinoma. Postoperative
course was uneventful. The patient returned to work after
two weeks. Subsequently, he came to oncology clinic for fur-
ther recommendations. The patient underwent staging CT
scans of the chest, abdomen, and pelvis with contrast which2 ISRN Oncology
did not reveal any evidence of residual malignancy. Because
of the size of the tumor and the grade, we offered him to
have right hemicolectomy. The patient was evaluated by a
colorectal surgeon and subsequently refused the procedure.
He also declined consideration of adjuvant chemotherapy.
After 3 months of followup, he remained asymptomatic and
did not keep his appointments after that.
3. LiteraturesReview
3.1. Epidemiology and Classiﬁcation. Cancer of the appendix
is very rare and is typically found incidentally in approx-
imately 1% of appendectomies [1]. According to a report
published by the National Cancer Institute using the Surveil-
lance, Epidemiology, and End Results (SEER) database, ap-
pendiceal neoplasms account for approximately 0.4% of
gastrointestinal tumors [2].
Even though primary appendiceal cancers are rare, there
is a diverse histology. Carcinoids are by far the most com-
mon, accounting for approximately 66%, with cystadenocar-
cinomaaccountingfor20%andadenocarcinomaaccounting
for 10% [1]. Then there are the rare forms of cancers which
include adenocarcinoid, signet ring, non-Hodgkin’s lym-
phoma, ganglioneuroma, and pheochromocytoma. Benign
pri-mary processes are mainly mucinous epithelial neo-
plasms,alsocalledadenomas,cystadenoma,andbenignneo-
plastic mucocele (Table 1). Frequency of appendiceal neo-
plasms found in 7970 appendectomy specimens is shown in
Table 1 [2].
Themajorityofprimarycancersoftheappendixoccurin
55–65 years of age, except formalignant carcinoid, which has
a mean age diagnosis of 38. Men and women seem to be at
equalriskforallappendicealneoplasmsexceptformalignant
carcinoid which may have woman to man ratio in excess of
3:1, depending on the studies that are analyzed [2].
3.2. Carcinoid Tumors. In 1907, German pathologist Dr.
Oberndorfer described a collection of tumors he found on
thesmallintestine aslooking likecarcinomabutalsoexhibit-
ing features of benign adenomas, as carcinoid (carcinoma-
like) [3]. In 1914, Dr Gosset and Dr Mason postulated that
carcinoid tumors were made up of enterochromaﬃn cells, a
type of neuroendocrine cells within the lamina propria and
submucosa. These cells produce and contain approximately
90% of the serotonin in our bodies [4].
It has been widely accepted that the majority of carci-
noids arise in the appendix,; however, recent data suggests
that other locations, such as the rectum and small intestine
may actually be more common [5]. In a study by Mggard
et al., 11,427 cases were analyzed, and it was found that
44.7% of tumors were found in the small intestine, 19.6%
in the rectum, 16.7% in the appendix, 10.6% in the colon,
and 7.2% in the stomach [5]. Data from the SEER database
also suggest that there is a greater proportion of pulmonary
and gastric carcinoids compared to appendiceal carcinoids,
however, these changes may be due to variation in reporting
as benign looking carcinoids were not added to the SEER
database until 1986 [6].
Table 1: Incidence of appendiceal neoplasms found in 7970 appen-
dectomy specimens.
Appendiceal neoplasm N
Carcinoid 42
Benign tumors
Mucinous cystadenoma 7
Villous adenoma 5
Malignant tumors
Adenocarcinoma 8
Lymphoma 1
Metastasis 11
Total 74
The incidence and prevalence of carcinoid tumors have
conﬂicting statistics. In many of the older articles, incidence
was stated as one to two in 100,000 [7, 8]. Newer data show
that the incidence may be double that. The inconsistency is
dueinparttothefactthatthediseaseismostlyasymptomatic
and can remain asymptomatic for many years, so the inci-
dence rate is more likely to be higher. Some research has
stated that carcinoid tumors are found in 1% of necropsies.
This would give a prevalence rate much higher than was pre-
viously accepted.
Most carcinoid tumors of the appendix are asymp-
tomatic. The average time for a carcinoid tumor to become
symptomatic is 9 years [9]. When the tumor is located in the
tip of the appendix, which it is in approximately 75% of the
cases, it generally does not present with symptoms until it
becomes metastatic. When the tumor is located at the base of
the appendix, it can occlude the lumen and give the patient
similar signs and symptoms of appendicitis [1]. In these
patients, the diagnosis of carcinoid cancer is typically made
by pathology after an appendectomy has been performed.
In rare cases, the patient can present with signs and
symptoms related to a carcinoid syndrome. These include
ﬂushing, tachycardia, severe explosive diarrhea, and hypot-
ension. These eﬀects are mostly caused by the serotonin that
the enterochromaﬃn cells are producing. The carcinoid tu-
mor also produces vasoactive substances such as histamine,
prostaglandins, kallikrein, bradykinins, substance P, gastrin,
corticotrophin, and neuron-speciﬁc enolase. The lungs and
the liver are able to clear many of these agents along with
the serotonin, therefore, able to avoid carcinoid syndrome.
It is not until these organs have carcinoid metastasis that
the ability to clear these substances becomes impaired, and
symptoms of carcinoid syndrome become apparent [9]. Car-
cinoid syndrome aﬀects approximately 10% of those with
carcinoid tumors.
As stated before, diagnosis of carcinoid tumor of the
appendix is usually made after an appendectomy. When the
patient presents with signs and symptoms of appendicitis,
a CAT scan of the abdomen is typically performed. These
imaging studies usually show a process of acute appendicitis
or have associated calciﬁcations [10, 11].ISRN Oncology 3
In a patient with suspected carcinoid syndrome, mea-
suring the urinary excretion of 5-HIAA and serum chromo-
granin A levels can be useful in diagnosis [9]. An OctreoScan
may be beneﬁcial; however, its results are not always reliable.
The extent of surgery is based upon the size of the tumor,
butsincethemajorityofcarcinoidtumorsarefoundinciden-
tally on simple appendectomies, a second surgery is some-
times needed. The National Comprehensive Cancer Network
(NCCN) guidelines for treatment of carcinoid tumors state
that tumors <2cm conﬁned to the appendix can be treated
with simple appendectomy with no followup required. For
tumors >2cm, or those with extra-appendigeal invasion, an
appendectomy with right hemicolectomy and cytoreductive
surgery is necessary. Post-operatively, a 3 month followup
which includes a history and physical (H&P), CT of the ab-
domen,andtestsformarkers(5-HIAAandchromograninA)
should be completed [2].
For patients with metastatic disease, somatostatin ana-
logs can be beneﬁcial in relieving the symptoms of carcinoid
syndrome. Somatostatin, an 18 amino-acid peptide, binds to
somatostatin receptors to block the secretion of hormones
such as growth hormones, gastrin, insulin, and glucagon.
These receptors are found on over 80% of carcinoid tumors
[12]. Octreotide, an eight-amino-acid, long-acting soma-
tostatin analogue, works through G-protein activation on
somatostatin receptor subtypes 2, 3, and 5 [13]. octreotide
was eﬀective in decreasing symptoms in 88% of patients and
decreasing the urinary 5-HIAA in 72% of patients [6]. In
patients who do not respond to octreotide, interferon-alpha
has been added with some positive results; however, as stated
by Mayer, this therapy comes at a cost of side eﬀects which
may include fever, fatigue, anorexia, and weight loss [6].
Generally, the prognosis for carcinoid tumors of the ap-
pendixisverygood.Ifthetumorisconﬁnedtotheappendix,
the disease is said to have 94 percent 5-year survival rate.
For patients with regional disease, there is an 85 percent 5-
year survival rate, and for distant metastasis, which occurs
in approximately 4% of the time in appendiceal carcinoid-
tumors, there is a 34 percent 5 year survival rate [8]. There is
still no accepted TMN-based staging system for carcinoid.
3.3. Benign Appendix Tumors. The endothelium of the ver-
miform appendix is composed of masses of lymph tissue
and is lined by mucous secreting columnar cells. Changes
to the columnar cells layer cause the four diﬀerent types of
pathology listed below.
(1) Retention cyst.
(2) Villous Hyperplasia.
(3) Cystadenoma.
(4) Cystadenocarcinoma.
Many consider these changes to be a spectrum of disease
much like colonic polyp formation and progression to carci-
noma in colon cancer. Like colon cancer, there are both hy-
perplasticandadenomatouschangesatthecellularlevel[12].
All of these changes cause the formation of a mucocele,
whichisdeﬁnedasadilationoftheappendixduetoexcessive
mucinous production. The mucin builds up due to a malig-
nant or non malignant obstruction of the outﬂow tract.
Retention Cysts. They occur when there is a nonmalignant
obstruction of the outﬂow tract of the appendix. The most
common cause of the obstruction is a fecalith. The epithelial
cells continue to produce mucin, and the appendix becomes
distended. There are no changes at the cellular level.
The vast majority of mucoceles measure less than 2cm,
and those that exceed 2cm are more likely to be neoplasms
[10, 11]. Most are clinically asymptomatic and are found
incidentally as palpable masses in the lower right quadrant
or on imaging performed for other reasons. On plain ab-
dominal ﬁlms, mucoceles are diﬃcult to appreciate. CT and
MRI are more eﬀective in identifying the extent of the mass.
Treatment is primarily surgical excision.
Villous Hyperplasia. It is also called hyperplastic polyp, and
has many of the same qualities of colonic polyps. The polyps
are sessile or ﬂat and do not have well-deﬁned borders. The
involvement is isolated to the mucosa. Instead of a fecalith
causing the obstruction as seen in retention cysts, the ob-
struction is caused by the hyperplastic polyp. Presentation,
imaging, and treatment are similar to the retention cyst.
Cystadenomas. They are the most common neoplasm of
the appendix. Much like the villous hyperplastic polyp, the
growth itself is what causes the formation of a mucocele.
Histologically, the lesion is benign; however, there may be a
continuum to cystadenocarcinomas. Most present as acute
appendicitis, and the treatment is surgical excision. Rupture
of the appendix can cause a phenomenon called pseudomyx-
oma peritonei which will be discussed later.
3.4. Malignant Appendix Tumors
Adenocarcinoma. Of the appendix is very rare, accounting
for 0.5% of all gastrointestinal cancers [14]. Within the ad-
enocarcinoma malignancies there are three subtypes: muci-
nous (55%), colonic type (34%), and adenocarcinoid (11%)
which has a mixed morphology. The mean age of diagnosis
is in the ﬁfth decade of life, with an even male to female ratio
for all but colonic type, which may have a higher incidence
inmen[1].Theincidenceofadenocarcinomahasbeenstated
to be from 0.004% to 0.08% [15].
Mucinous Adenocarcinoma. It is the malignant counterpart
to the mucinous adenoma. Both present with similar symp-
toms. Adenocarcinoid, also called Goblet cell carcinoid, has
features of both carcinoid tumor and mucinous adenocarci-
noma. They account for 5% of cancers of the appendix, with
anaverageagediagnosis of58years,andanevendistribution
between men and women [1].
Asisthecasewithmostcancersoftheappendix,themost
common presentation is that of acute appendicitis. This may
be from distention of the appendix causing pain or from a
superinfection. Those with mucinous adenocarcinoma may4 ISRN Oncology
present with a gradually distending abdomen which may be
seen with pseudomyxoma peritonei.
The mucinous type, also called mucinous cystadeno-
carcinoma, causes a mucocele by the neoplasm occluding
the narrow lumen which allows the mucin to build up and
distend the appendix. Perforation may occur allowing the
spillofcancerouscellsoutintotheperitoneum,whichcreates
the condition of pseudomyxoma peritonei. These cells then
seed the organs of the peritoneum and continue to produce
themucin.Asthemucinaccumulates,theabdomenbecomes
distended which is referred to as “jelly belly” [16]. Colonic
typeadenocarcinomaislesslikelytopresentwithamucocele.
Instead, they are more likely to present with a focal mass in
the right lower quadrant.
Adenocarcinoma. Adenocarcinoma of the appendix is rarely
diagnosed preoperatively. In a study by Nitecki et al., none of
the 96 patients with adenocarcinoma of the appendix were
diagnosed preoperatively, and it was only considered in the
diﬀerential diagnosis in 10 patients.
CT imaging is helpful in identifying a mucocele caused
by the neoplasm. Calciﬁcations increase the likelihood that
this process is malignant and not infective or inﬂammatory.
If there is a superinfection associated with the malignancy,
there may be air bubbles present on the CT. If the patient
presents with a distended abdomen due to pseudomyxoma
peritonei, a CT would show widespread heterogeneous locu-
les in the peritoneal cavity [10, 11]. Since there are no imag-
ingstudiesspeciﬁcfordiagnosingadenocarcinomas,theﬁnal
diagnosis is most often made postoperatively on microscopic
examination.
It hasbeen generallyacceptedthat a right hemicolectomy
is the preferred surgical intervention for all subtypes of
adenocarcinoma. While some surgeons suggest that a simple
appendectomy is suﬃcient for tumors exhibiting only local
disease,manystudieshaveshownthatthereisaclearsurvival
beneﬁt to the addition of a hemicolectomy [14, 17, 18]. In a
study by Nitecki, the 5-year survival rate for hemicolectomy
was 73% versus 44% in the appendectomy group. These
studies have found that the colonic and goblet cell subtypes
areinvasive,andapproximatelyhalfthepatientspresentwith
nodal metastasis [14]. However, there are some studies that
disagree. Gonzalez-Moreno and Sugarbaker found that those
patients with mucinous type cancer had no survival beneﬁt
from hemicolectomy versus appendectomy [19]. They fur-
ther mention that hemicolectomy is recommended in those
patients where (1) it is necessary to clear the tumor or per-
form complete cytoreduction; (2) lymph node involvement
is demonstrated by histopathological examination of the
appendiceal or ileocolic lymph nodes; or (3) a nonmucinous
subtype is identiﬁed by histopathological examination.
In a study done by Pahlavan and Kanthanon adenocar-
cinoid tumors, he states that even though Goblet cell car-
cinoma is an aggressive tumor, a simple appendectomy is
appropriate in most cases. However, he further states that a
right hemicolectomy should be performed in the following
scenarios:(1)cellularundiﬀerentiation,(2)increasedmitotic
activity, (3) involvement of the base of the appendix, (4)
lymph node metastasis, or (5) tumor size greater than 2cm
[20]. These guidelines allow the surgeon some direction in
deciding whether or not to reoperate after a patient has had
an appendectomy for an apparent appendicitis.
While there are small studies and anecdotal case reports
that suggest a response to regimens containing 5-FU, the
role of chemotherapy has yet to be clearly deﬁned. Most
oncologists agree that in the presence of nodal involvement,
systemic and intraperitoneal chemotherapy regimens should
be used [14, 16, 20]. Sugarland suggests postoperative in-
traperitoneal chemotherapy in the setting of pseudomyxoma
peritonei, as long as cytoreduction and debulking have been
accomplished, reducing recurrence rates [16].
Prognosis of adenocarcinoma depends on the subtype
and extent of disease. Mucinous adenocarcinoma is con-
sidered to have a more favorable prognosis because it does
exhibit hematogenous or lymphatic spread [16, 17]. While it
wouldbenaturaltoassumethatthosepatientswithintraper-
itoneal seeding due to appendiceal perforation, would have
a worse prognosis versus those who did not. However, in a
study by Nitecki and others, there actuall was no difference
in 5-year survival rates between the two groups [14]. Perfo-
ration did in often times lead to earlier medical intervention
and treatment.
Goblet cell subtype is considered to have a worse prog-
nosis with one study listing a 55% 5-year survival rate while
Pahlavan states a 60–80% 5-year survival rate [17, 20]. The
discrepancy may be due to diﬀerences in lymph node in-
volvementforthetwostudies.Theﬁrsthad43%lymphnode
involvement where Pahlavan only showed an 8.76% involve-
ment.
Lymphoma. The gastrointestinal tract is the most common
site for extranodal lymphoma. The stomach is the most
common, followed by the small intestine, pharynx, colon,
and esophagus. Lymphoma of the appendix is almost exclu-
sively non-Hodgkin’s B-cell lymphoma, more speciﬁcally,
Burkitt’s lymphoma. The incidence of primary appendiceal
lymphoma has been estimatedat 0.015% of appendectomy
specimens [21]. Men are more likely to develop appendiceal
lymphoma over women by 1.5:1, with a median age onset of
18 years [22].
As so many other primary tumors of the appendix, pa-
tients typically present with symptoms similar to acute ap-
pendicitis. Patients may also present with a more insidious
onset of pain in the right iliac fossa for a few months and an
associated palpable mass in the right lower quadrant.
When imaging is done, the appendix demonstrates
prominent enlargement, while it maintains the vermiform
appearance [10, 11]. On ultrasound, the diﬀuse thickening is
hypoechoicandoftenmimicsthecysticdilationofthelumen
seen in mucoceles.
As with all lymphoma’s, chemotherapy is the mainstay
of treatment. The classic combination of cyclophosphamide,
doxorubicin, vincristine, and prednisone (CHOP) has been
used for many decades, and since the Groupe d’Etude des
Lymphomas de l’Adulte study, Rituximab has been added
[23]. Rituximab, a monoclonal antibody against CD20, was
found to increase complete response rates from 64% to
76% [24]. It was also found that the CHOP plus RituximabISRN Oncology 5
increasedeventfreestatesandoverallsurvival.Thecombina-
tion of CHOP and rituximab is now the standard of care for
large B-cell lymphoma in the US. For Burkitt’s lymphoma, a
more aggressive chemotherapy regimen is in need.
Primary Signet Ring Cell Carcinoma. Primary Signet Ring
Cell Carcinoma of the appendix is a very rare cancer. Ac-
cording to the data gathered from the SEER database, the
incidence is approximately 0.15, with an average age of 59,
and there is no male or female preference. Of all the subtypes
of appendiceal cancers, signet ring had the lowest percentage
of localized disease at 14%, and the highest percentage of
distant disease at 60%. The most common presentation is
of acute appendicitis, and the recommended surgical inter-
vention is of a right hemicolectomy [25]. The prognosis is
considered very poor [1]. Of all the subtypes, signet ring
had the lowest overall 5-year survival rate at 18%. Those
who presented with distant disease had a 5-year survival of
7%. The role of chemotherapy as a treatment in signet ring
cancers of the appendix has not been determined.
Ganglioneuroma. It is an extremely rare cancer that is asso-
ciated with neuroﬁbromatosis, MEN 2b, congenital defects,
carcinomas, and various polyp forming diseases [13]. A
searchoftheliteratureshowedonlythreecasereportsofgan-
glioneuromas involving the appendix, all being the Neu-
roﬁbromatosis type 1 [26–28]. Two of the cases presented
as discomfort in the lower right quadrant, while the third
presented as a palpable mass found on physical exam. All
three patients underwent surgical removal of the tumor and
the involved surrounding tissue.
In those patients with Neuroﬁbromatosis 1 and MEN 2b,
pheochromocytomas are also prevalent and may be found as
a primary cancer of the appendix. This is extremely rare, and
there is very little data available to extrapolate meaningful
conclusions at this time.
4. Discussion
Appendix cancer is rare, and most commonly found inci-
dentally in an appendectomy specimen that was obtained for
an unrelated condition. The main histologic types are car-
cinoids, adenocarcinomas, adenocarcinoids, cystadenomas,
and cystadenocarcinomas. For appendiceal carcinoids, re-
operation and right colectomy is recommended for tumors
larger than 2cm and for smaller tumors with mesoappen-
diceal invasion. Most patients have localized disease, and the
prognosis is excellent.
Thespectrumofepithelialtumorsoftheappendixranges
from the benign mucocele to an aggressive adenocarcinoma.
Simple appendectomy, taking care not to rupture the tumor
intraoperatively, is suﬃcient therapy for benign appendiceal
mucoceles, cystadenomas, and some cystadenocarcinomas.
A right colectomy is indicated for cystadenocarcinomas with
mesenteric or adjacent organ involvement and complicated
mucoceles with involvement of the terminal ileum or cecum,
cystadenocarcinomas.
Pseudomyxoma peritonei (PMP) is a unique condition
characterized by diﬀuse collections of gelatinous material in
the abdomen and pelvis, associated with mucinous implants
on the peritoneal surfaces. The term should be reserved for
the clinical situation in which a ruptured cystadenoma seeds
the peritoneal cavity with mucus-producing epithelial cells,
termed diﬀuse peritoneal adenomucinosis (DPAM). The
naturalhistoryisoneofindolentbutprogressivegrowth,and
if left untreated, this is a fatal condition. Standard treatment
for PMP is repeated surgical debulking for symptomatic
disease. This treatment is not curative but aims to limit the
buildup of mucus and its pressure eﬀe c t .Am o r ea g g r e s -
sive approach using radical surgical cytoreduction of all
intraabdominalandpelvicdiseaseandintraperitonealheated
chemotherapy (IPHC) has been adopted by some clinicians,
aiming for cure. Although randomized trials have not been
c o n d u c t e d ,ﬁ v e - y e a rs u r v i v a lr a t e so f7 0t o8 6p e r c e n th a v e
been reported for highly selected patients. The importance
of surgical technique and surgeon experience to the success
and safety of this approach cannot be overemphasized.
In contrast to other appendiceal tumors, adenocarcino-
mas more often present with a clinical picture of acute ap-
pendicitis. Standard treatment is a right colectomy. The role
of adjuvant chemotherapy for adenocarcinoma of the ap-
pendix is unknown. Despite the lack of available data, many
oncologists recommend adjuvant 5-FU-based chemother-
apy particularly for patients with node-positive intestinal
type adenocarcinoma, extrapolating from data on adjuvant
chemotherapy for node-positive colon cancer. Optimal
treatment of patients with intraperitoneal dissemination of
appendiceal adenocarcinoma (mucinous peritoneal carcino-
matosis as distinguished from DPAM) is unclear. Selected
patients treated with aggressive surgical cytoreduction and
IPHC may do well-long term, but patient selection and the
experience of the treating team are critical. In uncontrolled
series from experienced institutions, long-term survival rates
in highly selected patients range from 28 to 72 percent at
three to 10 years. The beneﬁt of systemic chemotherapy for
advanced disease is unknown. Although mucinous appen-
diceal adenocarcinomas have been thought to be relatively
chemotherapy refractory, case reports suggest some level of
beneﬁt for therapy in individual patients.
The cancers of the appendix could represent a challenge
for diagnosis and management. No standard of care is
established due to rare frequency of occurrence, our case and
the literature review are a summary of the appendix tumor,
and the management based more on personal opinion of the
oncologists who deal with this rare type of tumor, hopefully,
would help in the future to create clinical trials to establish
more evidence-based medicine help in the management.
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